Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SOX10 mutations that disrupt the SOX10-β-catenin interaction partially prevented tumor suppression.
|
25301735 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The selected markers included CK5/6, p40, CK19, BerEP4, p16 and SOX10.All tumors were CK5/6 and p40 positive.
|
31548087 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With the automated algorithm there was an inverse correlation between the SOX10 staining intensity and the proliferation marker, Ki-67 (ρ=-0.173, P=0.02) and a significant difference in the intensity signal between the benign tissues, the primary tumors and the metastases where the metastases stained the weakest (P≤0.001).
|
20890226 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All the tumors showed strong diffuse MUC4 expression (n=15), and SOX10 was positive in all nine breast and in five out of six salivary gland tumors.
|
28548128 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study provides evidence that the tumor suppressor Fbxw7α is the E3 ubiquitin ligase responsible for the degradation of SOX10, and suggests that reduced Fbxw7α might contribute to the upregulation of SOX10 in melanoma cells.
|
26461473 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Positive staining for SOX10 and the S100 protein are often used in the evaluation of challenging melanocytic neoplasms including melanoma in patient samples.
|
30950082 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX10 immunohistochemistry may be of utility in distinguishing some of the varying adnexal tumors from each other, and from basal cell carcinoma (BCC), but given the staining of both apocrine and eccrine tumors, does not seem to provide information as to their origins as either eccrine or apocrine tumors.
|
28343365 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of the small round blue cell morphology and negative immunohistochemical staining for pan-melanocytic cocktail (HMB45, anti MART1 and anti-tyrosinase) and SOX10 in both cases, FLI-1 immunostaining was requested as part of the tumors workup.
|
28605142 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX10 is a sensitive diagnostic marker in all AdCCs, which could potentially aid in diagnosis of these tumors on limited material.
|
31105427 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among 47 previously diagnosed nonmelanocytic malignant effusions (4 malignant mesotheliomas, 12 müllerian tumors, 9 breast carcinomas, 9 lung adenocarcinomas, and 13 hematologic tumors), SOX10 and HMB45 showed a specificity of 98%, whereas Melan A and S100 had a specificity of 100%.
|
30794352 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical studies demonstrated the tumor cells to be PAX-8 (+), pancytokeratin (+, focally), TTF-1 (-) and SOX-10 (-).
|
26347145 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings were compared with those of previous studies that evaluated SOX10 in tumors of the skin.
|
30531326 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of an increasing need to preserve limited diagnostic material for tumor genotyping and a mounting demand for cost containment, the authors investigated the usefulness of dual-color IHC with antibodies directed against broad-spectrum keratins and SOX10, a neuroectodermal transcription factor consistently expressed in melanoma, in the workup of epithelioid malignant neoplasms.
|
29385322 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study revealed a miR-31-SOX10 axis that regulated tumor growth and resistance to chemotherapy of melanoma.
|
29969627 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To study the molecular pathways contributing to the formation of MPNSTs in NF1 patients, we used a zebrafish tumor model defined by nf1 loss in a p53-deficient background together with the overexpression of either wild-type or constitutively activated PDGFRA (platelet-derived growth factor receptor-α) under control of the sox10 neural crest-specific promoter.
|
27477693 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SOX10 is also highly expressed in melanoma tumors, and SOX10 expression increases with tumor progression.
|
29315345 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this article we thoroughly evaluated SOX10 expression in salivary gland tumors.
|
27327192 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Only focal areas demonstrated expression of HMB-45 and SOX-10, supporting the melanocytic origin of the tumor.
|
29405341 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, our results demonstrate that CMTM7 as a tumor suppressor is down-regulated in gastric cancer, and SOX10 can regulate the proliferation and tumor formation of gastric cancer by regulating the expression of CMTM7.
|
30392914 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SOX10 is important in nonneoplastic oligodendroglial development, but mRNA transcripts and protein expression are identified in a wider variety of CNS glial neoplasms than oligodendrogliomas.
|
26945037 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All Moloney murine leukemia virus/PDGFB tumors had a high protein expression of Sox10 independently of malignant grade or tumor type.
|
17855658 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All in all, SOX10 is a commonly activated tumor promoter that activates Wnt/β-catenin signaling in cancer cells of HCC.
|
25001176 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SOX10 expression in the basal-like and unstable molecular subtypes supports the concept that these neoplasms show myoepithelial differentiation.
|
29894722 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The retrovirally tagged genes Plekhb1, Prex1, Prkg2, Sox10 and 1200004M23Rik were upregulated in the tumors but had a different expression profile than Pdgfralpha whereas Rap1gap, Gli1, Neurl and Camk2b were downregulated in the tumors.
|
15750623 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By immunohistochemistry, these tumors show expression of S100 protein and SOX10, in the absence of expression of more specific melanocytic markers (eg, HMB45, Melan A).
|
27346570 |
2016 |